参考文献
1: Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015 Dec;102:63-70. doi: 10.1016/j.phrs.2015.09.012. Epub 2015 Sep 15. Review. PubMed PMID: 26384444.
2: Zhang Y, Li S, He L, Wang F, Chen K, Li J, Liu T, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, Xia Y, Zhou Y, Lu J, Guo C. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther. 2015 May 25;9:2757-66. doi: 10.2147/DDDT.S79837. eCollection 2015. Review. PubMed PMID: 26045661; PubMed Central PMCID: PMC4448927.
3: Simó R, Simó-Servat O, Hernández C. Is fenofibrate a reasonable treatment for diabetic microvascular disease? Curr Diab Rep. 2015 May;15(5):24. doi: 10.1007/s11892-015-0599-0. Review. PubMed PMID: 25772642.
4: Schofield JD, Liu Y, France MW, Sandle L, Soran H. A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report. J Clin Lipidol. 2014 Jul-Aug;8(4):455-9. doi: 10.1016/j.jacl.2014.05.003. Epub 2014 Jun 6. Review. PubMed PMID: 25110229.
5: Hernández Mijares A. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies]. Clin Investig Arterioscler. 2014 Jul;26 Suppl 1:25-30. doi: 10.1016/S0214-9168(14)70023-3. Review. Spanish. PubMed PMID: 25043544.
6: Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013 Dec;62(12):3968-75. doi: 10.2337/db13-0800. Review. PubMed PMID: 24264394; PubMed Central PMCID: PMC3837039.
7: Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol. 2013 Sep 27;5(9):470-8. doi: 10.4254/wjh.v5.i9.470. Review. PubMed PMID: 24073298; PubMed Central PMCID: PMC3782684.
8: Attridge RL, Frei CR, Ryan L, Koeller J, Linn WD. Fenofibrate-associated nephrotoxicity: a review of current evidence. Am J Health Syst Pharm. 2013 Jul 15;70(14):1219-25. doi: 10.2146/ajhp120131. Review. PubMed PMID: 23820458.
9: Simó R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem. 2013;20(26):3258-66. Review. PubMed PMID: 23745548.
10: Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013 May;43(5):522-31. doi: 10.1111/eci.12068. Epub 2013 Mar 11. Review. PubMed PMID: 23480615.
11: Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, Hou R, Qin Y. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol. 2012 Nov 1;110(9):1296-301. doi: 10.1016/j.amjcard.2012.06.050. Epub 2012 Jul 27. Review. PubMed PMID: 22840347.
12: Wong TY, Simó R, Mitchell P. Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol. 2012 Jul;154(1):6-12. doi: 10.1016/j.ajo.2012.03.013. Review. PubMed PMID: 22709833.
13: Farnier M. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia. Expert Rev Cardiovasc Ther. 2012 May;10(5):565-75. doi: 10.1586/erc.12.37. Review. Erratum in: Expert Rev Cardiovasc Ther. 2013 Feb;11(2):253-4. PubMed PMID: 22651832.
14: Elijah IE, Børsheim E, Maybauer DM, Finnerty CC, Herndon DN, Maybauer MO. Role of the PPAR-α agonist fenofibrate in severe pediatric burn. Burns. 2012 Jun;38(4):481-6. doi: 10.1016/j.burns.2011.12.004. Epub 2012 Jan 9. Review. PubMed PMID: 22226866; PubMed Central PMCID: PMC3669757.
15: Susekov AV, Khokhlova NV. [Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?]. Kardiologiia. 2011;51(9):68-74. Review. Russian. PubMed PMID: 21943011.
16: McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 2011 Oct 1;71(14):1917-46. doi: 10.2165/11208090-000000000-00000. Review. PubMed PMID: 21942979.
17: Simó R, Hernández C. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate. Rev Recent Clin Trials. 2012 Feb;7(1):71-80. Review. PubMed PMID: 21864248.
18: Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011 Aug;12(12):1945-58. doi: 10.1517/14656566.2011.593509. Epub 2011 Jul 8. Review. PubMed PMID: 21736529.
19: Keating GM. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review. PubMed PMID: 21675801.
20: Hermans MP. Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res. 2011 Jul;8(3):180-9. doi: 10.1177/1479164111407783. Epub 2011 May 16. Review. PubMed PMID: 21576195.
